Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 Feb 2018 Planned number of patients changed from 65 to 66.
- 17 Jan 2018 Planned number of patients changed from 46 to 65.
- 17 Jan 2018 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.